STAT3 and neoplasm: In addition, the release of EVs and IL-6 from colon cancer cells could be mitigated by treating tumor cells with atractylenolide I (an EV biogenesis inhibitor by regulating the STAT3 pathway in tumor cells), and consequently attenuate weight loss in tumor-bearing mice[147].